PetVivo Holdings Inc. | Income Statement

Fiscal year is April-March. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
-
75.00
7.10
1.50
Cost of Goods Sold (COGS) incl. D&A
75.90
-
743.60
746.80
643.40
Gross Income
75.90
-
668.60
739.70
641.90
SG&A Expense
23,324.70
1,201.90
2,582.60
1,568.90
1,643.40
EBIT
23,400.70
1,201.90
3,251.20
2,308.60
2,285.30
Unusual Expense
-
35.30
216.90
14,056.60
22.00
Non Operating Income/Expense
-
-
-
32.00
-
Interest Expense
12.40
399.20
1,262.80
188.50
74.00
Pretax Income
23,413.10
1,565.70
4,730.80
16,521.70
2,337.30
Consolidated Net Income
23,413.10
1,565.70
4,730.80
16,521.70
2,337.30
Net Income
23,413.10
1,565.70
3,651.70
15,531.50
2,337.30
Net Income After Extraordinaries
23,413.10
1,565.70
3,651.70
15,531.50
2,337.30
Net Income Available to Common
23,413.10
1,565.70
3,651.70
15,531.50
2,337.30
EPS (Basic)
33.23
0.21
0.46
1.73
0.14
Basic Shares Outstanding
753.20
7,609.40
7,853.90
8,955.20
16,943.90
EPS (Diluted)
31.08
0.21
0.46
1.73
0.14
Diluted Shares Outstanding
753.20
7,609.40
7,853.90
8,955.20
16,943.90
EBITDA
23,400.70
1,201.90
2,507.60
1,561.80
1,641.90
Minority Interest Expense
-
-
1,079.10
990.20
-

About PetVivo Holdings

View Profile
Address
5251 Edina Industrial Boulevard
Edina Minnesota 55439
United States
Employees -
Website http://www.petvivo.com
Updated 07/08/2019
PetVivo Holdings, Inc. engages in the licensing and commercialization of medical devices and therapeutics for pets. It offers Kush system for the treatment of osteoarthritis and lameness in dogs and horses. The company was founded by John Lai and John F.